ADRB1 and esophageal squamous cell carcinoma: Elevated ADRB1 expression could serve as an important marker of poor prognosis following neoadjuvant immune chemotherapy, and ADRB1 inhibition may offer a novel therapeutic approach to enhance the efficacy of immune treatments in ESCC.